Author

William Nowatzke

PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES
PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES

William Nowatzke  et al.

SZN-1326, A WNT MIMETIC, IMPROVED EPITHELIAL HEALING AND DECREASED COLLAGEN DEPOSITION IN A DEXTRAN SULFATE SODIUM-INDUCED COLITIS MOUSE MODEL
SZN-1326, A WNT MIMETIC, IMPROVED EPITHELIAL HEALING AND DECREASED COLLAGEN DEPOSITION IN A DEXTRAN SULFATE SODIUM-INDUCED COLITIS MOUSE MODEL

William Nowatzke  et al.

SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES
SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES

William Nowatzke  et al.

SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL
SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL

William Nowatzke  et al.

Item 1 - 4 / 4
1